HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jéssica Leite Garcia Selected Research

gamma-oryzanol

11/2021Antioxidant and anti-inflammatory properties of gamma- oryzanol attenuates insulin resistance by increasing GLUT- 4 expression in skeletal muscle of obese animals.
10/2021Gamma-oryzanol reduces renal inflammation and oxidative stress by modulating AGEs/RAGE axis in animals submitted to high sugar-fat diet.
1/2021Gamma-oryzanol as a potential modulator of oxidative stress and inflammation via PPAR-y in adipose tissue: a hypothetical therapeutic for cytokine storm in COVID-19?
1/2018Gamma Oryzanol Treats Obesity-Induced Kidney Injuries by Modulating the Adiponectin Receptor 2/PPAR-α Axis.
11/2017Effect of Gamma-Oryzanol as Therapeutic Agent to Prevent Cardiorenal Metabolic Syndrome in Animals Submitted to High Sugar-Fat Diet.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jéssica Leite Garcia Research Topics

Disease

10Obesity
03/2022 - 11/2017
7Inflammation (Inflammations)
03/2022 - 01/2018
6Body Weight (Weight, Body)
01/2021 - 11/2017
3Insulin Resistance
11/2021 - 09/2019
3Dyslipidemias (Dyslipidemia)
04/2021 - 09/2018
2Weight Gain
11/2018 - 11/2017
1Necrosis
03/2022
1Type 2 Diabetes Mellitus (MODY)
11/2021
1Virus Diseases (Viral Diseases)
01/2021
1Cardiomyopathies (Cardiomyopathy)
01/2021
1Cytokine Release Syndrome
01/2021
1COVID-19
01/2021
1Hypertension (High Blood Pressure)
11/2018
1Cardiovascular Diseases (Cardiovascular Disease)
11/2018
1Wounds and Injuries (Trauma)
01/2018
1Metabolic Diseases (Metabolic Disease)
01/2018
1Kidney Diseases (Kidney Disease)
11/2017
1Hypertriglyceridemia
11/2017
1Metabolic Syndrome (Dysmetabolic Syndrome X)
11/2017
1Proteinuria
11/2017

Drug/Important Bio-Agent (IBA)

5gamma-oryzanolIBA
11/2021 - 11/2017
5Triglycerides (Triacylglycerol)IBA
01/2021 - 11/2017
4SugarsIBA
03/2022 - 11/2017
4AntioxidantsIBA
11/2021 - 11/2017
4Glucose (Dextrose)FDA LinkGeneric
01/2021 - 11/2017
3Proteins (Proteins, Gene)FDA Link
04/2021 - 11/2017
3Uric Acid (Urate)IBA
01/2021 - 11/2017
2Interleukin-6 (Interleukin 6)IBA
03/2022 - 04/2021
2CreatinineIBA
04/2021 - 11/2017
2CytokinesIBA
01/2021 - 01/2021
2Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2021 - 01/2018
2LycopeneIBA
10/2020 - 09/2019
2Insulin (Novolin)FDA Link
11/2018 - 11/2017
2CholesterolIBA
11/2018 - 09/2018
1Malondialdehyde (Propanedial)IBA
03/2022
1Superoxide DismutaseIBA
03/2022
1CatalaseIBA
03/2022
1Glucose Transporter Type 4IBA
11/2021
1Toll-Like Receptor 4IBA
01/2021
1Corn Oil (Oil, Corn)IBA
10/2020
1CalciumIBA
10/2020
1Adrenergic Agents (Adrenergic Drugs)IBA
09/2019
1LipidsIBA
11/2018
1HDL LipoproteinsIBA
11/2018
1EnzymesIBA
01/2018
1Adiponectin ReceptorsIBA
01/2018

Therapy/Procedure

2Therapeutics
03/2022 - 01/2021